Leidos(US:LDOS)2026-02-17 14:02Financial Data and Key Metrics Changes - In 2025, the company recorded revenues of $17.2 billion, an increase of 3.1% year-over-year, while Q4 revenue was $4.2 billion, a decrease of 3.6% year-over-year [31][5] - Adjusted EBITDA margin for 2025 was 14.1%, a year-over-year increase of 120 basis points, while Q4 adjusted EBITDA margin was 13.2%, up 160 basis points year-over-year [5][33] - Non-GAAP diluted earnings per share (EPS) for 2025 was $11.99, a 17% increase from the previous year, with Q4 EPS at $2.76 [35][5] - Free cash flow for 2025 was $1.63 billion, representing a 104% conversion rate, while Q4 free cash flow was $452 million [44][42] Business Line Data and Key Metrics Changes - All four segments contributed to revenue growth in 2025, with Defense Systems showing robust revenue growth due to increased production of munitions and systems [41][36] - The Health and Civil segment saw a slight revenue increase for the year but a decrease for the quarter, impacted by the transition of electronic health records [38][39] - The Commercial International segment experienced growth driven by improved performance in the UK and increased engineering support for commercial utilities [40][39] Market Data and Key Metrics Changes - The company reported net bookings of $5.6 billion in Q4, maintaining a book-to-bill ratio of 1.3 times, with a year-over-year funded backlog increase of 15% [6][5] - The company anticipates revenue growth in 2026 to be between $17.5 billion and $17.9 billion, reflecting growth of up to 4% over 2025 [46] Company Strategy and Development Direction - The company is executing its North Star 2030 strategy, focusing on profitable growth and aligning with administration priorities [11][20] - Significant investments are being made in growth pillars, including a planned tripling of capital expenditures to $350 million in 2026 [19][49] - The company is actively pursuing co-investment opportunities with the Department of Defense and other agencies to enhance its growth strategy [60][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate challenges, including a government shutdown, and highlighted strong demand across various sectors [4][5] - The company expects to see growth accelerate in the second half of 2026, driven by new program wins and a robust business development pipeline [65][66] - Management noted that the backlog and pending awards position the company well for future growth, despite some delays in award activity [67][72] Other Important Information - The company has made strategic acquisitions, including Kudu Dynamics, to enhance its capabilities in cyber and technology [14][15] - The company is realigning its organizational structure to better execute its growth strategy, maintaining focus on five sectors [21][20] Q&A Session Summary Question: Investment areas for additional CapEx - Management confirmed investments in co-development opportunities with the Department of Defense and other sectors, emphasizing a broad strategy for growth [60][61] Question: Early year growth expectations - Management indicated lower growth in the first half of 2026, with expectations for acceleration in the latter half due to new program wins and a robust pipeline [63][66] Question: Book-to-bill activity and future expectations - Management highlighted a strong pipeline and backlog, expecting continued order activity and growth in the coming year [72][73] Question: VA medical exam recompete - Management expressed confidence in maintaining market share and profitability in the health sector, with an RFP expected mid-year [85][86] Question: FY 2026 growth guidance and conservatism - Management acknowledged potential upside in growth and margins based on defense funding decisions and FAA modernization initiatives [92][94] Question: Product and defense tech areas - Management provided updates on key programs like IFPC and hypersonics, indicating strong growth potential in defense technology [100][101]